Clinical Trials Logo

Filter by:
NCT ID: NCT03931252 Withdrawn - Cystic Fibrosis Clinical Trials

Thermic Effect of Feeding in Cystic Fibrosis

Start date: January 2022
Phase: N/A
Study type: Interventional

The investigators propose to assess the contributions of the thermic effect of food intake (TEF), which is the amount of energy expended to digest food, to overall energy expenditure in Cystic Fibrosis (CF).

NCT ID: NCT03929211 Withdrawn - Clinical trials for Myelodysplastic Syndromes

CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome

Start date: May 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2 study of the combination of CPI-613 and hydroxychloroquine for the treatment of high risk myelodysplastic syndrome patients who have failed a hypomethylating agent.

NCT ID: NCT03928808 Withdrawn - Anorexia Nervosa Clinical Trials

Fecal Microbiota Transplantation (FMT) in Treatment of Severe and Enduring Anorexia Nervosa

Start date: April 1, 2023
Phase: Early Phase 1
Study type: Interventional

This is an open-label pilot study designed to explore the safety, feasibility, tolerability, and acceptability of fecal microbiota transplantation (FMT) in the treatment of severe and enduring anorexia nervosa (SE-AN).

NCT ID: NCT03928639 Withdrawn - Heart Failure Clinical Trials

Structural Heart and Valve Network PROSPECTIVE Registry

Start date: January 10, 2023
Phase:
Study type: Observational

Background: Treatments for structural heart and valve disease are quickly changing. But treatment could be improved. Researchers want to gather data from people with this disease. They want to find problems and seek new ways to make treatments better. Objective: To find people with structural heart and valve disease with common features to study. To find flaws and patterns in procedures related to this disease. To share findings with other researchers. Eligibility: People ages 18 and older who are receiving care from the structural heart and valve program at the participating NHLBI structural heart disease network sites that are part of the study Design: Participants will be screened with their consent. This will occur when they give their standard consent for medical care. Participants will have their data collected in the course of standard medical care. Data include: Demographic data Protected health data Personally identifiable data Medical records Medical images. These could include X-rays, CT scans, and MRI scans. The study could find something that would impact participants care. If this is the case, their doctors will be told. Participants data may be shared with other researchers. ...

NCT ID: NCT03928015 Withdrawn - Pain, Acute Clinical Trials

Evaluation of Dronabinol For Acute Pain Following Traumatic Injury

Start date: October 1, 2019
Phase: Phase 2
Study type: Interventional

Single center, non-blinded, randomized controlled trial. Enrollment is based on ≥50 MME within 24 hours of admission, followed by a 24 hour screening/randomization window and a participation period extending through the acute hospitalization period. A total of 122 adult patients admitted with a traumatic injury will be randomized 1:1 across 2 study arms: adjunctive dronabinol or systemic analgesics only. Patients randomized to the dronabinol arm should receive their first dose within 12 hours of randomization; patients will also receive PRN as needed systemic analgesics for pain. Except for the analgesia protocol, all other interventions will be equivalent for participants in both arms. The clinical effects of analgesia treatment arm will be evaluated during the acute hospitalization (hospital admission through discharge or death). The primary efficacy endpoint will be assessed starting at 48 hours after randomization and carried through to discharge.

NCT ID: NCT03927625 Withdrawn - Safety Clinical Trials

Evaluation of Ascorbate-Meglumine Therapeutic for SRS

Start date: December 1, 2021
Phase: Phase 1
Study type: Interventional

Phase 1, Single-Center, Dose-Escalating, Open-Label, Safety Clinical Trial of Parenteral Ascorbate-Meglumine as a Novel Magnetic Resonance Imaging-guided Adjunctive Therapeutic for Stereotactic Radiosurgery (SRS).

NCT ID: NCT03926546 Withdrawn - OCD Clinical Trials

Individual Versus Group Exposure With Response Prevention (ERP) for the Treatment of Obsessive Compulsive Disorder (OCD)

Start date: May 2020
Phase: N/A
Study type: Interventional

The primary objective is to examine the efficacy of implementing evidence based Exposure and Response Prevention (ERP) within group therapy versus individual therapy by monitoring reduction of Obsessive-Compulsive Disorder (OCD) symptomology.

NCT ID: NCT03924297 Withdrawn - PTSD Clinical Trials

Chilipad for Sleep and Symptoms of PTSD

Start date: September 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to obtain pilot data in preparation for future research designed to formally evaluate the effectiveness of the Chilipad for patients with PTSD

NCT ID: NCT03924102 Withdrawn - Clinical trials for Acute Decompensated Heart Failure

Cardiac Perfusion and Metabolism With [11C] Acetate PET/CT is Associated With Hematopoietic System Activation in Acute Decompensated Heart Failure: An Imaging Sub-study

Start date: December 31, 2025
Phase: Phase 1
Study type: Interventional

The purpose of this sub-study is to use positron emission tomography and computed tomography imaging (PET/CT) with an investigational drug called [11C] acetate to see if inflammation in patients with acute decompensated heart failure (ADHF) can cause changes in blood flow and oxygen use in the heart. This study may help physicians better understand how to treat patients diagnosed with ADHF in the future.

NCT ID: NCT03924024 Withdrawn - Orthopaedic Trauma Clinical Trials

rTMS for Orthopaedic Trauma Patients

Start date: August 1, 2019
Phase: N/A
Study type: Interventional

This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for orthopaedic trauma patients. In this open label study, all participants will receive accelerated theta-burst stimulation. This study will examine whether symptoms of psychiatric distress and opioid use in orthopaedic trauma patients can be mitigated with rTMS to improve post-injury recovery.